Lacosamide is Used for treating partial-onset seizures in patients with epilepsy aged 17 years and older, either as adjunctive therapy or when oral treatment is temporarily not feasible. It was first introduced by Ucb Inc in its drug Vimpat on Oct 28, 2008. Another drug containing Lacosamide is Motpoly Xr. 35 different companies have introduced drugs containing Lacosamide.

Lacosamide Patents

Given below is the list of patents protecting Lacosamide, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Motpoly Xr	US11337943	Lacosamide pharmaceutical composition and dosage form thereof	Jun 05, 2040	Aucta
Motpoly Xr	US11883374	Lacosamide pharmaceutical composition and dosage form thereof	Jun 05, 2040	Aucta
Motpoly Xr	US12042474	Lacosamide pharmaceutical composition and dosage form thereof	Jun 05, 2040	Aucta
Vimpat	USRE38551	Anticonvulsant enantiomeric amino acid derivatives	Mar 17, 2022 (Expired)	Ucb Inc
Vimpat	US5654301	Amino acid derivative anticonvulsant	Aug 05, 2014 (Expired)	Ucb Inc

Add above patents to watchlist

Lacosamide's Family Patents

Full family tree

Lacosamide Generic API Manufacturers

Several generic applications have been filed for Lacosamide. The first generic version for Lacosamide was by Mylan Pharmaceuticals Inc and was approved on Apr 28, 2016. And the latest generic version is by Ajenat Pharmaceuticals Llc and was approved on Jun 26, 2025.

Given below is the list of companies who have filed for Lacosamide generic, along with the locations of their manufacturing plants worldwide.